Investing.com - Biondvax Pharma ADR reported on Thursday second quarter earnings that missed analysts' forecasts and revenue that was inline with expectations.
Biondvax Pharma ADR announced earnings per share of ₪-0.0061 on revenue of ₪0.00. Analysts polled by Investing.com anticipated EPS of ₪0.00 on revenue of ₪0.00.
Biondvax Pharma ADR shares are down 50.3% from the beginning of the year, still down 66.53% from its 52 week high of ₪3.49 set on December 22, 2021. They are under-performing the Nasdaq which is down 19.92% from the start of the year.
Biondvax Pharma ADR shares lost 0.14% in intra-day trade following the report.
Biondvax Pharma ADR follows other major Healthcare sector earnings this month
Biondvax Pharma ADR's report follows an earnings missed by Eli Lilly on August 4, who reported EPS of ₪1.25 on revenue of ₪6.49B, compared to forecasts EPS of ₪1.7 on revenue of ₪6.85B.
Pfizer had beat expectations on July 28 with second quarter EPS of ₪2.04 on revenue of ₪27.74B, compared to forecast for EPS of ₪1.72 on revenue of ₪25.49B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar